Publikationen (51) Publikationen von Teresa Lozano Moreda

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. FOXP3 expression diversifies the metabolic capacity and enhances the efficacy of CD8 T cells in adoptive immunotherapy of melanoma

    Molecular Therapy, Vol. 31, Núm. 1, pp. 48-65

  2. Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses

    Cancer Letters, Vol. 561

  3. PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

    Cancer Research, Vol. 83, Núm. 15, pp. 2513-2526

  4. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

  5. The transcriptional regulator Sin3A balances IL-17A and Foxp3 expression in primary CD4 T cells

    EMBO Reports, Vol. 24, Núm. 5

2022

  1. BACH2 restricts NK cell maturation and function, limiting immunity to cancer metastasis

    Journal of Experimental Medicine, Vol. 219, Núm. 12

  2. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

    Science Advances, Vol. 8, Núm. 39

  3. Impact of tumor microenvironment on adoptive T cell transfer activity

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 1-31

  4. Intratumoral electroporation of a self-amplifying RNA expressing IL-12 induces antitumor effects in mouse models of cancer

    Molecular Therapy - Nucleic Acids, Vol. 29, pp. 387-399

  5. Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy

    OncoImmunology, Vol. 11, Núm. 1

  6. TCR-induced FOXP3 expression by CD8+ T cells impairs their anti-tumor activity

    Cancer Letters, Vol. 528, pp. 45-58

  7. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 8

2021

  1. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

    Journal of Nanobiotechnology, Vol. 19, Núm. 1

  2. Enhanced recovery after low- and medium-risk liver transplantation. A single-center prospective observational cohort study

    International Journal of Surgery, Vol. 85, pp. 46-54

  3. Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma

    BioMed Research International, Vol. 2021

  4. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

  5. Searching for peptide inhibitors of t regulatory cell activity by targeting specific domains of foxp3 transcription factor

    Biomedicines, Vol. 9, Núm. 2, pp. 1-20

2020

  1. A cell-based bioluminescence assay reveals dose-dependent and contextual repression of AP-1-driven gene expression by BACH2

    Scientific Reports, Vol. 10, Núm. 1

  2. A distal enhancer at risk locus 11q13.5 promotes suppression of colitis by Treg cells

    Nature, Vol. 583, Núm. 7816, pp. 447-452